P-Akt expression distinguishes two types of malignant rhabdoid tumors
✍ Scribed by Aubri Charboneau; Jingjing Chai; Jennifer Jordan; William Funkhouser; Alexander Judkins; Jaclyn Biegel; Bernard Weissman
- Publisher
- John Wiley and Sons
- Year
- 2006
- Tongue
- English
- Weight
- 196 KB
- Volume
- 209
- Category
- Article
- ISSN
- 0021-9541
No coin nor oath required. For personal study only.
✦ Synopsis
Abstract
Highly aggressive pediatric malignant rhabdoid tumors (MRT) arise in the kidney and central nervous system (CNS) with no curative treatment available. Multiple studies have shown that inactivation of the SNF5 tumor suppressor gene occurs in virtually all MRTs. However, few studies have addressed whether additional genetic events may contribute to MRT development. In this report, we demonstrate that phosphorylated Akt (P‐Akt) is expressed in a subpopulation of cells in at least 10% of primary rhabdoid tumors as well as at high levels in three MRT cell lines. Similar to other high P‐Akt expressing tumor cell lines, MRTs have decreased sensitivity to p21 induced growth arrest. Therefore, P‐Akt expression may distinguish between two types of MRTs. Because drugs directed against the PI3‐K/Akt have shown promise in clinical trials for other tumor types, they may prove useful for treatment of patients with P‐Akt positive MRTs. P‐Akt expression also provides a potential mechanistic link between these pediatric tumors and adult malignancies. J. Cell. Physiol. 209: 422–427, 2006. © 2006 Wiley‐Liss, Inc.